Skip to main content
Tessa NewsLink
Paste a health news link, or browse

Source study found

Story checked

3D printing-inspired technology can improve dosing accuracy for personalized medicines (opens in a new tab)

news-medical.net · 2026-10-08

Short answerEvidenceSource

Short answer

Not supported

Not supported.

One key claim is not backed by the study. One other point was not covered by the paper.

  • 2 overstated
  • 1 not supported
  • 1 not covered

Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.

Share this check

Follow the evidence trail
1
2

NewsLink checks it

Not supported

Three claims go beyond the study. Two overstate it and one isn't supported at all. One claim the study doesn't address.

  • 2 overstated
  • 1 not supported
  • 1 not covered
Open claim evidence
3
Then inspect each claim

Evidence layer

Claim by claim

Each claim gets a verdict. Expand it to see the evidence directly below.

4 claims in this story

Showing all 4 claimsChoose a verdict to focus the list.

Claim 1 of 4Not supportedThe article says the approach may benefit children, older patients, people with rare diseases, hospital patients who need frequent dose adjustments, and situations where medicine shortages limit access to commercial products.View evidenceHide evidence

Why this verdict

The supplied abstract profile reports in vitro pharmacopeial quality metrics for 3D-printed metoprolol tablets. It does not provide evidence about benefits for children, older patients, rare-disease patients, hospital patients needing frequent dose adjustment, or medicine-shortage situations. The claim is hedged, but these population/access benefits are not supported by the supplied paper profile.

1

Study evidence

Automated 3D printing produced low-dose metoprolol tablets with mean API contents of 90–103%, SDs below 5%, and USP <905> acceptance values under 15 across all evaluated sites and formulations.Mean API 90–103%; SD <5%; AV <15

“CurifyLabs' Compounding System, including the Pharma Printer and CuraBlend®-based formulations, was used at two hospital pharmacy sites and a compounding pharmacy to produce 6.25 mg and 12.5 mg tablets via 3D printing.”
Claim 2 of 4OverstatedMahsa Bahman’s doctoral thesis at Åbo Akademi University investigated how a 3D printing-inspired technology can improve dosing accuracy and make customized treatments more widely available.View evidenceHide evidence

As statedimprove dosing accuracy; make customized treatments more widely available

Why this verdict

The abstract-level profile supports an in vitro comparison in which automated 3D printing produced low-dose metoprolol tablets with more consistent API content than manually split tablets. That supports a dose-accuracy angle. However, the story/headline broadens this to Mahsa Bahman’s doctoral thesis, customized treatments generally, and wider availability/access, none of which is established in the supplied abstract profile. The headline framing therefore outruns the paper evidence.

1

Study evidence

Manually split 6.25 mg (quarter) fragments exhibited extreme variability in API content.24.9% to 142.8% of label claim

“Commercial 25 mg metoprolol tartrate tablets from two manufacturers were manually split at Mayo Clinic into 12.5 mg halves and 6.25 mg quarters”
2

Study evidence

Automated 3D printing produced low-dose metoprolol tablets with mean API contents of 90–103%, SDs below 5%, and USP <905> acceptance values under 15 across all evaluated sites and formulations.Mean API 90–103%; SD <5%; AV <15

“CurifyLabs' Compounding System, including the Pharma Printer and CuraBlend®-based formulations, was used at two hospital pharmacy sites and a compounding pharmacy to produce 6.25 mg and 12.5 mg tablets via 3D printing.”
Claim 3 of 4OverstatedThe research examined whether the technology can manufacture a wide range of personalised medicines and evaluated dose accuracy, product quality, stability, consistency, and performance in a hospital pharmacy environment.View evidenceHide evidence

Why this verdict

The paper profile supports evaluation of dose accuracy/content uniformity, mass variation, and multi-site consistency for 3D-printed low-dose metoprolol tablets in hospital/compounding pharmacy settings, using USP <905>-style criteria and HPLC. But the story claim overstates the scope by saying the research examined a wide range of personalised medicines and stability; the supplied profile covers one drug at two strengths and explicitly does not report longer-term stability or broad product ranges at abstract depth.

1

Study evidence

Manually split 6.25 mg (quarter) fragments exhibited extreme variability in API content.24.9% to 142.8% of label claim

“Commercial 25 mg metoprolol tartrate tablets from two manufacturers were manually split at Mayo Clinic into 12.5 mg halves and 6.25 mg quarters”
2

Study evidence

Automated 3D printing produced low-dose metoprolol tablets with mean API contents of 90–103%, SDs below 5%, and USP <905> acceptance values under 15 across all evaluated sites and formulations.Mean API 90–103%; SD <5%; AV <15

“CurifyLabs' Compounding System, including the Pharma Printer and CuraBlend®-based formulations, was used at two hospital pharmacy sites and a compounding pharmacy to produce 6.25 mg and 12.5 mg tablets via 3D printing.”
Claim 4 of 4Not coveredThe technology uses a 3D printing-inspired manufacturing process that dispenses carefully measured amounts of a gel-like formulation to produce medicines in individually tailored doses.View evidenceHide evidence

As statedindividually tailored doses

Why this verdict

The abstract supports use of CurifyLabs' 3D-printing/automated compounding system with CuraBlend-based formulations to produce 6.25 mg and 12.5 mg metoprolol tablets. But the abstract profile does not verify the described gel-like dispensing mechanism or that the doses were individually patient-tailored rather than two evaluated fixed strengths. Those manufacturing-mechanism details may require full-text evidence.

1

Study evidence

Automated 3D printing produced low-dose metoprolol tablets with mean API contents of 90–103%, SDs below 5%, and USP <905> acceptance values under 15 across all evaluated sites and formulations.Mean API 90–103%; SD <5%; AV <15

“CurifyLabs' Compounding System, including the Pharma Printer and CuraBlend®-based formulations, was used at two hospital pharmacy sites and a compounding pharmacy to produce 6.25 mg and 12.5 mg tablets via 3D printing.”
Then look for missing context

Context layer

What the story left out

Important study details the story did not include.

  • The central study is a specific comparison of manual splitting of commercial 25 mg metoprolol tablets versus automated 3D printing of 6.25 mg and 12.5 mg metoprolol tablets, assessed with USP <905>-style criteria and validated HPLC.

    The story reflects a general 3D-printing/personalized-medicine theme but omits the specific drug, dose strengths, comparator, and analytical framework that define the profiled paper.

    From in_vitro; in_vitro pharmacopeial quality testing (multi-site)

  • Manually split metoprolol fragments showed substantial dose-content variability, including quarter-tablet API content ranging from 24.9% to 142.8% of label claim.

    The story emphasizes the promise of 3D-printing-inspired manufacturing but does not mention the manual tablet-splitting comparator or the magnitude of variability that motivated the comparison.

    From in_vitro

  • The abstract profile does not report stability testing or long-term manufacturing robustness over time.

    This is an interpretation-changing limitation because the story says stability was evaluated or improved, while the supplied profile states that stability/longer-term robustness is not reported at abstract depth.

    From in_vitro pharmacopeial quality testing (multi-site)

3 things the story did carry across
  • 3D-printed metoprolol tablets achieved mean API contents within 90–103%, standard deviations below 5%, and USP acceptance values under 15 across evaluated sites and formulations.
  • The 3D-printing work was evaluated across two hospital pharmacy sites and one compounding pharmacy, supporting a limited multi-site reproducibility claim.
  • The evidence is in vitro pharmacopeial quality testing; clinical performance, patient outcomes, and bioequivalence were not assessed in the abstract profile.
Then read the study layer

Study layer

Study at a glance

Scan the study first. Expand only the parts you want to inspect.

Pieces of work

2

Evidence read

study summary

Lead result

in vitro

1Lead resultin vitroCompare dose accuracy and content uniformity of low-dose metoprolol produced by manual tablet splitting versus automated 3D printing in a hospital pharmacy setting using USP <905> criteria and validated HPLC assay.in vitroExpand

In plain English

In an in vitro hospital-pharmacy evaluation, commercially produced 25 mg metoprolol tartrate tablets were manually split into 12.5 mg halves and 6.25 mg quarters and analyzed for mass variation and API content uniformity using USP <905>-style criteria and a validated HPLC assay. Manually split fragments showed very high variability in API content, including quarters with content ranging from 24.9% to 142.8% of label strength and halves from one manufacturer averaging 66.6% of label strength.

Key findings

  • Manually split 6.25 mg (quarter) fragments exhibited extreme variability in API content.24.9% to 142.8% of label claim
  • Manually split 12.5 mg (half) fragments from one manufacturer showed systematic underdosing on average.mean ~66.6% of label claim
“Commercial 25 mg metoprolol tartrate tablets from two manufacturers were manually split at Mayo Clinic into 12.5 mg halves and 6.25 mg quarters”
What this piece can’t prove
  • Abstract does not specify how many tablets/fragments were analyzed or the distribution of results across manufacturers and sites.

2 further details could not be confirmed from the summary.

2in vitroAssess reproducibility/consistency of 3D-printed metoprolol tablets across multiple production sites (two hospital pharmacy sites and a compounding pharmacy) and formulations within the CurifyLabs system.in vitro pharmacopeial quality testing (multi-site)Expand

In plain English

In an in vitro, multi-site pharmacopeial quality assessment, CurifyLabs' automated 3D printing (Pharma Printer with CuraBlend® formulations) produced 6.25 mg and 12.5 mg metoprolol tartrate tablets at two hospital pharmacy sites and one compounding pharmacy. Mass variation and content uniformity were assessed by USP <905>-style criteria using a validated HPLC assay. Across sites and formulations, 3D-printed tablets showed mean API contents of 90–103%, standard deviations below 5%, and USP acceptance values under 15, indicating consistent dose content by the reported metrics.

Key findings

  • Automated 3D printing produced low-dose metoprolol tablets with mean API contents of 90–103%, SDs below 5%, and USP <905> acceptance values under 15 across all evaluated sites and formulations.Mean API 90–103%; SD <5%; AV <15
  • The CurifyLabs system was implemented at multiple production sites (two hospital pharmacy sites and one compounding pharmacy) and yielded consistent pharmacopeial quality metrics across those locations.
“CurifyLabs' Compounding System, including the Pharma Printer and CuraBlend®-based formulations, was used at two hospital pharmacy sites and a compounding pharmacy to produce 6.25 mg and 12.5 mg tablets via 3D printing.”
What this piece can’t prove
  • Only in vitro pharmacopeial quality tests (mass variation/content uniformity) are reported; clinical performance or bioequivalence is not assessed.

2 further details could not be confirmed from the summary.

Finally, the search trail

Method layer

NewsLink found the paper. Tessa takes you deeper.

NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.

Papers considered

The selected paper, plus nearby candidates.

PubMed, Europe PMC, Crossref · 15 candidate papers

And 9 more candidates considered.